Conavi Medical Corp. CNVIF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 106.37% | 134.65% | -97.46% | -24.44% | -84.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.37% | 134.65% | -97.46% | -24.44% | -84.48% |
| Cost of Revenue | -- | -- | -- | -92.64% | -99.79% |
| Gross Profit | 109.60% | -6.14% | -96.91% | 818.56% | 205.66% |
| SG&A Expenses | 44.32% | 50.11% | 41.87% | -10.69% | -44.36% |
| Depreciation & Amortization | 36.88% | -5.85% | -10.65% | -17.50% | -9.56% |
| Other Operating Expenses | -- | -- | 54.13% | -83.52% | -- |
| Total Operating Expenses | 38.99% | -9.87% | -35.64% | -19.45% | -50.09% |
| Operating Income | -38.07% | 11.42% | -2,019.77% | 19.07% | 48.54% |
| Income Before Tax | -77.63% | -60.30% | 61.39% | 58.17% | 72.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.63% | -60.30% | 61.39% | 58.17% | 72.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.63% | -60.30% | 61.39% | 58.17% | 72.97% |
| EBIT | -38.07% | 11.42% | -2,019.77% | 19.07% | 48.54% |
| EBITDA | -37.74% | 11.28% | -1,324.03% | 19.94% | 49.18% |
| EPS Basic | -17.55% | 29.07% | 79.81% | 96.66% | 97.57% |
| Normalized Basic EPS | -17.45% | 25.65% | 30.70% | 94.31% | 96.94% |
| EPS Diluted | -17.55% | 29.07% | 79.81% | 96.66% | 97.57% |
| Normalized Diluted EPS | -17.45% | 25.65% | 30.70% | 94.31% | 96.94% |
| Average Basic Shares Outstanding | 51.00% | 125.74% | 91.35% | 1,151.98% | 1,012.79% |
| Average Diluted Shares Outstanding | 51.00% | 125.74% | 91.35% | 1,151.98% | 1,012.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |